These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6238245)

  • 21. Reduced brain delivery of homovanillic acid to cerebrospinal fluid during human aging.
    Rapoport SI; Schapiro MB; May C
    Arch Neurol; 2004 Nov; 61(11):1721-4. PubMed ID: 15534183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of action tremor in multiple sclerosis with isoniazid.
    Sabra AF; Hallett M; Sudarsky L; Mullally W
    Neurology; 1982 Aug; 32(8):912-3. PubMed ID: 7201590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease.
    Manyam BV; Ferraro TN; Hare TA
    Brain Res; 1987 Apr; 408(1-2):125-30. PubMed ID: 2885064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid.
    Ebinger G; Michotte Y; Herregodts P
    J Neurochem; 1987 Jun; 48(6):1725-9. PubMed ID: 3572399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.
    Carpenter LL; Moreno FA; Kling MA; Anderson GM; Regenold WT; Labiner DM; Price LH
    Biol Psychiatry; 2004 Sep; 56(6):418-26. PubMed ID: 15364040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease.
    Ishibashi K; Kanemaru K; Saito Y; Murayama S; Oda K; Ishiwata K; Mizusawa H; Ishii K
    Acta Neurol Scand; 2010 Jul; 122(1):46-51. PubMed ID: 20002007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic nicotine modifies the effects of morphine on extracellular striatal dopamine and ventral tegmental GABA.
    Vihavainen T; Relander TR; Leiviskä R; Airavaara M; Tuominen RK; Ahtee L; Piepponen TP
    J Neurochem; 2008 Nov; 107(3):844-54. PubMed ID: 18786163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled trial of isoniazid therapy for action tremor in multiple sclerosis.
    Bozek CB; Kastrukoff LF; Wright JM; Perry TL; Larsen TA
    J Neurol; 1987 Jan; 234(1):36-9. PubMed ID: 3546605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of isoniazid therapy in Huntington disease.
    McLean DR
    Neurology; 1982 Oct; 32(10):1189-91. PubMed ID: 6214730
    [No Abstract]   [Full Text] [Related]  

  • 30. Isoniazid and Huntington's chorea.
    Perry TL
    N Engl J Med; 1978 May; 298(19):1092-3. PubMed ID: 148007
    [No Abstract]   [Full Text] [Related]  

  • 31. A specific and sensitive determination of gamma aminobutyric acid in CSF and brain tissue by gas chromatography-mass spectrometry.
    Schaaf JM; Teelken AW; Muskiet FA; Nagel G; Wolthers BG
    J Neurosci Methods; 1985 May; 13(3-4):257-65. PubMed ID: 4010335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid homovanillic acid in cerebral infarction.
    Hachinski V; Shibuya M; Norris JW; Hornykiewicz O
    J Neural Transm Suppl; 1978; (14):45-50. PubMed ID: 290739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The content of dopamine, its metabolites and GABA in the nigrostriatal system of rats with different learning abilities].
    Karpova IV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1992; 42(1):161-3. PubMed ID: 1316006
    [No Abstract]   [Full Text] [Related]  

  • 34. Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease.
    Manyam BV; Giacobini E; Colliver JA
    J Neurol; 1990 Aug; 237(5):281-4. PubMed ID: 2146369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiseizure activity of gamma-acetylenic gamma-aminobutyric acid: a catalytic irreversible inhibitor of gamma-aminobutyric acid transaminase.
    Schechter PJ; Tranier Y; Jung MJ; Sjoerdsma A
    J Pharmacol Exp Ther; 1977 Jun; 201(3):606-12. PubMed ID: 864598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease.
    Achar VS; Welch KM; Chabi E; Bartosh K; Meyer JS
    Neurology; 1976 Aug; 26(8):777-80. PubMed ID: 133299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in understanding Huntington's chorea.
    Barbeau A
    Can J Neurol Sci; 1975 May; 2(2):81-5. PubMed ID: 124199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid.
    Ben-Menachem E; Persson LI; Mumford J; Haegele KD; Huebert N
    J Child Neurol; 1991; Suppl 2():S11-6. PubMed ID: 1719063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of intracaudate administration of kainic acid on the activity of the dopaminergic system].
    Zharkovskiĭ AM; Nurk AM
    Fiziol Zh SSSR Im I M Sechenova; 1981 Nov; 67(11):1606-10. PubMed ID: 6799331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind clinical trial of isoniazid in Huntington disease.
    Perry TL; Wright JM; Hansen S; Thomas SM; Allan BM; Baird PA; Diewold PA
    Neurology; 1982 Apr; 32(4):354-8. PubMed ID: 6460947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.